The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | QUACK: patient-reported symptom burden as a prognostic factor

Name: QUACK: patient-reported symptom burden as a prognostic factor
Uploaded: 2020-07-02T00:00:00Z
Duration: 1 min 53 s
Description: Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, outlines patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer, as evaluated in the Phase II QUACK study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Kensei Yamaguchi • 2 Jul 2020

ESMO WCGIC 2020

Colorectal Cancer Gastrointestinal Cancer Antibodies Cetuximab

QUACK

Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, outlines patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer, as evaluated in the Phase II QUACK study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).